



PRODUCT: **RINVOQ™**

COMPANY: AbbVie, Inc.

Therapeutic Area & Indication:

JAK (Janus kinase) inhibitor that blocks inflammation of moderate to severe rheumatoid arthritis (RA) in patients who don't benefit from existing treatments

About the Product

RINVOQ (upadacitinib) is a once-daily oral Janus kinase (JAK) inhibitor approved for the treatment of moderate to severe rheumatoid arthritis (RA) by the U.S. Food and Drug Administration as well as regulatory agencies in many other countries. Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Previously, JAK inhibition was not a widely accepted area of study in immunology, but AbbVie's team designed, synthesized and tested more than 3,000 molecules to find RINVOQ — the best combination of affinity, selectivity and desirable pharmacokinetic properties.